(ASRT) Assertio Therapeutics - Ratings and Ratios

Assertio Holdings, Inc. (NASDAQ:ASRT) is a commercial-stage pharmaceutical company specializing in the development and marketing of therapeutic products. Its portfolio includes INDOCIN, an NSAID used for treating rheumatoid arthritis, ankylosing spondylitis, and gouty arthritis, available in oral and suppository forms. Sympazan, a benzodiazepine, is indicated for seizures in Lennox-Gastaut syndrome patients. CAMBIA, another NSAID, targets migraine symptoms, while Zipsor and SPRIX provide pain relief. Otrexup offers a single-dose methotrexate solution for rheumatoid arthritis and psoriasis. ROLVEDON, a G-CSF, reduces infection risk in febrile neutropenia. The company, rebranded in 2020, focuses on niche markets and is based in Lake Forest, Illinois.

Technically, ASRT trades at $0.82 with a 20-day volume of 351,904. The SMA20 at $0.81 and SMA50 at $0.83 suggest near-term stability, but the SMA200 at $1.07 indicates a longer-term downtrend. The ATR of $0.04 signals low volatility, implying small price movements.

Fundamentally, ASRTs market cap is $81.80M with a forward P/E of 9.78, indicating expected growth despite a current P/E of 0. The P/B of 0.57 and P/S of 0.61 suggest undervaluation, but the RoE of -52.47 highlights significant losses, raising profitability concerns.

3-Month Forecast: ASRT may face downward pressure due to poor fundamentals, with potential range-bound trading between $0.75 and $0.90. The bearish SMA200 and negative RoE could limit upside, despite the markets growth expectations reflected in the forward P/E.